| DAIICHI SANKYO COMPANY, LIMITED Patent applications |
| Patent application number | Title | Published |
|---|
| 20120129891 | SULFONE DERIVATIVE - Provided are a compound having an excellent hypoglycemic action, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause an increase in the blood sugar level due to abnormal sugar metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed. | 05-24-2012 |
| 20120129832 | AMIDE DERIVATIVE - Provided are a compound having an excellent hypoglycemic action, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause an increase in the blood sugar level due to abnormal sugar metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed. | 05-24-2012 |
| 20120129762 | MOTILIN-LIKE PEPTIDE COMPOUND HAVING TRANSMUCOSAL ABSORBABILITY IMPARTED THERETO - The present invention aims at providing motilin-like peptide compounds that maintain the gastrointestinal motility stimulating activity of native motilin and which are adapted to have higher absorbability upon transmucosal administration. | 05-24-2012 |
| 20120114711 | PHARMACEUTICAL COMPOSITION HAVING IMPROVED SOLUBILITY - It is desired to provide a pharmaceutical composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof, or a solvate thereof, which exhibits an inhibitory effect on activated blood coagulation factor X (FXa), and is useful as an agent for preventing and/or treating thrombosis, wherein the pharmaceutical composition exhibits favorable dissolution properties. The present invention relates to a solid pharmaceutical composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof, or a solvate thereof, wherein the content of the compound represented by formula (I) is 0.5% by weight or more and less than 15% by weight with respect to the total weight of the pharmaceutical composition. | 05-10-2012 |
| 20120108639 | NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND - The present invention provides a compound having excellent regulating action on blood lipid level that is represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein, in one embodiment, A represents a 5-membered nitrogen-containing aromatic heterocyclyl group; R | 05-03-2012 |
| 20120094383 | METHODS FOR INDUCING CELL DEATH IN PLURIPOTENT STEM CELLS AND DIFFERENTIATED CELLS OTHER THAN CARDIAC MYOCYTES - The present invention has as its object developing a method that does not involve genomic modification and which yet is capable of inducing cell death in pluripotent stem cells such as embryonic stem cells and induced pluripotent stem cells, as well as in differentiated cells other than cardiomyocytes derived from pluripotent stem cells, but not in cardiomyocytes. It has been revealed that by establishing a method capable of inducing cell death in cells other than cardiomyocytes in a very efficient manner by adding a substance having no recognized inherent toxicity or cell death inducing action to the culture conditions for pluripotent stem cells and non-cardiomyocytes, the stated problem can be solved without relying upon genomic modification. | 04-19-2012 |
| 20120077980 | METHOD FOR PRODUCING A SOLID PREPARATION - A method for producing a solid preparation containing a compound represented by the formula (I) below or a pharmacologically acceptable salt thereof, which includes a step wherein a composition containing the compound represented by the formula (I) below or a pharmacologically acceptable salt thereof is mixed, while applying a mechanical stress to the composition. The compound of the formula (I) is as follows: | 03-29-2012 |
| 20120071685 | METHOD FOR PRODUCING BICYCLIC gamma-AMINO ACID DERIVATIVE - Methods for producing compounds having activity as an α | 03-22-2012 |
| 20120071665 | METHOD FOR PRODUCING OLMESARTAN MEDOXOMIL - A method for producing high-purity olmesartan medoxomil is provided in which a solvent containing water is used in steps of tritylation and DMDO esterification of olmesartan. | 03-22-2012 |
| 20120071476 | MORPHOLINOPURINE DERIVATIVES - There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity: | 03-22-2012 |
| 20120071467 | AMIDE DERIVATIVE - Compounds or pharmacologically acceptable salts thereof are provided. In various embodiments the compounds have an antagonistic effect on a neurokinin NK | 03-22-2012 |
| 20120064158 | DISSOLUTION PROPERTIES OF DRUG PRODUCTS CONTAINING OLMESARTAN MEDOXOMIL - A pharmaceutical tablet containing olmesartan medoxomil and amlodipine besylate, which has improved dissolvability. Said composition contains (A) olmesartan medoxomil and (B) amlodipine besylate as active ingredients and (C) a calcium-containing additive. A method of improving the dissolution properties of a pharmaceutical composition containing olmesartan medoxomil and amlodipine besylate by using said composition is also provided. | 03-15-2012 |
| 20120059172 | NOVEL SOLVATE CRYSTALS - Acetone solvate crystals of trityl olmesartan medoxomil are provided. | 03-08-2012 |
| 20120046327 | METHOD FOR INHIBITING THE INDUCTION AND FORMATION OF OSTEOCLASTS - Methods for (i) inhibiting the induction and formation of osteoclasts, (ii) inhibiting RANKL expression in osteoblasts, (ii) inhibiting the activation of osteoclasts and (iv) inhibiting a decrease in bone density by administering to a warm-blooded animal in need thereof a pharmacologically effective amount of a compound selected from the group consisting of olmesartan and olmesartan medoxomil, a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof. | 02-23-2012 |
| 20120041206 | PROCESS FOR PRODUCING DIAMINE DERIVATIVE - The problem to be solved is to provide an important intermediate for production of an FXa inhibitor. The solution thereto is a process for industrially producing a compound (1) represented by the following formula (1): | 02-16-2012 |
| 20120040936 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP - Low molecular weight compound exhibiting an osteogenesis-promoting action having the general formula (I) or a pharmacologically acceptable salt thereof: | 02-16-2012 |
| 20120035369 | METHOD FOR PRODUCING OPTICALLY ACTIVE DIAMINE DERIVATIVE - The problem to be solved is to provide an important intermediate for production of an FXa inhibitor. The solution thereto is a method for industrially producing a compound (1) or a compound (4), comprising: [Step 1]: adding a quaternary ammonium salt and a metal azide salt to water to prepare an aqueous solution of an azidification reagent complex comprising quaternary ammonium salt-metal azide salt, and subsequently dehydrating the aqueous solution using an aromatic hydrocarbon solvent to form a mixed solution of the azidification reagent complex comprising quaternary ammonium salt-metal azide salt and the aromatic hydrocarbon solvent with a water content of 0.2% or less; and [Step 2]: adding, to the mixed solution prepared in [Step 1], a compound (2) wherein L represents a leaving group. | 02-09-2012 |
| 20120034215 | ANTI-MST1R ANTIBODIES AND USES THEREOF - The present disclosure provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for MST1R, which plays an integral role in various disorders or conditions, such as cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the disclosure also can be used in the diagnostics field, as well as for further investigating the role of MST1R in the progression of disorders associated with tumors. The disclosure also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 02-09-2012 |
| 20120029026 | PYRIDINE DERIVATIVE - The present invention relates to a novel pyridine derivative or a pharmacologically acceptable ester thereof, or a pharmacologically acceptable salt of the derivative or ester, which has an excellent hypoglycemic effect or treats and/or prevents the onset of a disorder of carbohydrate or lipid metabolism or a disease mediated by peroxisome proliferator-activated receptor (PPAR) γ. A compound represented by the general formula (I): | 02-02-2012 |
| 20110319468 | CYCLIC AMINE COMPOUNDS - Compounds exhibiting calcium receptor antagonist activity that are safe and orally administrable having Formula (I) or pharmaceutically acceptable salts thereof | 12-29-2011 |
| 20110319359 | INDANYL COMPOUNDS - Compounds exhibiting calcium receptor antagonist activity that are safe and orally administrable having Formula (I) or pharmaceutically acceptable salts thereof: | 12-29-2011 |
| 20110312991 | ACTIVATED BLOOD COAGULATION FACTOR INHIBITOR - An object of the present invention is to provide a novel salt form of a compound that exhibits an inhibitory effect on activated blood coagulation factor X, and is useful as a preventive and/or therapeutic drug for thrombotic diseases, and crystals thereof. The present invention provides N | 12-22-2011 |
| 20110312990 | Diamine Derivatives - A compound represented by the general formula (1): | 12-22-2011 |
| 20110281823 | Pharmaceutical preparation containing an angiotensin II Receptor antagonist, a calcium channel blocker and polyvinyl alcohol - A pharmaceutical preparation including a pharmacologically effective amount of a combination of active ingredients containing an angiotensin II receptor antagonist, a calcium channel blocker and polyvinyl alcohol, wherein the polyvinyl alcohol is in an amount of 5 to 85% by weight of the total weight of the pharmaceutical preparation. A method for the prophylaxis or treatment of hypertension by administering a pharmaceutically effective amount of the pharmaceutical preparation to a patient. | 11-17-2011 |
| 20110275821 | METHOD FOR PRODUCING DIAMINE DERIVATIVE - The present invention provides a method for producing a compound represented by formula (A), the method comprising the steps of: (a) mixing a compound represented by formula (B) with p-toluenesulfonic acid or p-toluenesulfonic acid monohydrate at less than 1 molar equivalent with respect to the compound represented by formula (B) in a solvent under heating; (b) adding additional p-toluenesulfonic acid or p-toluenesulfonic acid monohydrate to the mixed solution under cooling, wherein the additional p-toluenesulfonic acid or p-toluenesulfonic acid monohydrate is added in such an amount that the total molar equivalent thereof with the p-toluenesulfonic acid or p-toluenesulfonic acid monohydrate of step (a) is 1 molar equivalent or more with respect to the compound represented by formula (B) of step (a); and (c) subsequently allowing the mixed solution to crystallize to obtain the compound represented by formula (A). | 11-10-2011 |
| 20110275666 | ACTIVATED BLOOD COAGULATION FACTOR X (FXA) INHIBITOR - An object of the present invention is to provide an activated blood coagulation factor X (FXa) inhibitor that reduces the risk of bleeding caused by the treatment of thromboembolism. The present invention provides an oral anticoagulant agent comprising a compound represented by the following formula (1): | 11-10-2011 |
| 20110269942 | ANTIBODIES MODIFIED WITH HYDROPHOBIC MOLECULE - The present invention relates to an immunoliposome preparation or a hydrophobic molecule-modified antibody having a therapeutic effect on cancer, autoimmune disease, or inflammatory disease. Specifically, the present invention relates to an immunoliposome or a hydrophobic molecule-modified antibody comprising, as a constituent, an antibody capable of inducing the apoptosis of cells expressing a death domain-containing receptor. | 11-03-2011 |
| 20110269746 | CYCLIC COMPOUND HAVING HETERO ATOM - Compounds exhibiting an osteogenesis-promoting action having the general formula (I) or a pharmacologically acceptable salt thereof: | 11-03-2011 |
| 20110263673 | Atropisomers of (Hydroxyalkyl) Pyrrole Derivatives - The present invention comprises a compound for the prevention and/or treatment of cardiovascular diseases. The compound is an atropisomer of a compound represented by the following general formula (I): wherein R | 10-27-2011 |
| 20110263544 | 1-Phenylpyrrole Derivatives - The present invention comprises a compound for the prevention and/or treatment of cardiovascular diseases, nephropathy, fibrosis, primary aldosteronism or edema. The compound is of the following general formula (I): wherein R | 10-27-2011 |
| 20110257401 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID - It has been demanded to provide a process for industrially producing an intermediate for a compound that exhibits an inhibitory effect on activated blood coagulation factor X and is useful as a preventive and/or therapeutic agent for thrombotic diseases. The present invention provides a process for producing the (R)-α-phenylethylamine salt of (S)-3-cyclohexene-1-carboxylic acid, comprising reacting 3-cyclohexene-1-carboxylic acid and (R)-α-phenylethylamine using a mixed solvent of water and acetone or a mixed solvent of water and ethyl acetate as a solvent. | 10-20-2011 |
| 20110256188 | DRY POWDER PHARMACEUTICAL COMPOSITION FOR INHALATION - There is provided a dry powder pharmaceutical composition for inhalation useful for preventing and/or treating influenza virus infections contains as a medicinal component a compound represented by formula (I): | 10-20-2011 |
| 20110223175 | Gene Encoding G-Protein Coupled Receptor And Gene Product Thereof - The present invention, the objects of which are to find out a gene encoding a protein having functions equivalent to those of G-protein-coupled receptor (GPCR) and the protein, and to provide a method for identifying a compound that regulates functions and/or expression of the protein, and to provide a useful mean for preventing and/or treating diseases related to the gene and the protein, provides a DNA comprising base sequence described in SEQ ID NO: 1 or complementary strand thereof, complementary strand of the DNA, a protein encoded by the DNA, a vector containing the DNA, a transformant containing the vector, an antibody against the protein, a method for identifying a compound that regulates functions and/or expression of the protein using aforementioned members, an agent for improving and a method for improving depression state, a pharmaceutical composition, and a reagent kit. | 09-15-2011 |
| 20110201814 | METHOD FOR PRODUCING SOLID PREPARATION - A method for producing a solid preparation containing a compound represented by the formula (I) below or a pharmacologically acceptable salt thereof, which comprises a step wherein a composition containing the compound represented by the general formula (I) below or a pharmacologically acceptable salt thereof is mixed, while applying mechanical stress to the composition. The compound of the formula (I) is as follows: | 08-18-2011 |
| 20110166343 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY - To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): | 07-07-2011 |
| 20110166342 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF - A 7-membered heterocyclic compound having the formula (I), or its salt, or a solvate thereof with a chymase inhibitory action and useful for the prevention or treatment of various diseases, in which chymase is involved: | 07-07-2011 |
| 20110160462 | CRYSTALLINE FORMS OF THIAZOLIDINEDIONE COMPOUND AND ITS MANUFACTURING METHOD - Thiazolidinedione compound crystalline forms useful as a bulk material for the manufacture of a peroxisome proliferator-activated receptor (PPAR) γ activator or an anticancer pharmaceutical composition are provided, which are hydrate crystalline forms of 5-(4-{[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1-H-benzimi dazol-2-yl]methoxy}benzyl)-1,3-thiazolidine-2,4-dione represented by Formula (I) below and of its dihydrochloride. | 06-30-2011 |
| 20110159049 | PHARMACEUTICAL COMPOSITION - The present invention relates to a granular pharmaceutical composition comprising a drug having a disagreeable taste, a wax and a sugar alcohol; a method for preparing the same; and a pharmaceutical product for oral administration, comprising the granular composition. The product excellently masks a disagreeable taste possessed by a drug and provides good sensation upon oral administration, and therefore is easily ingested by even the elderly, children, and patients suffering dysphagia. Moreover, the product is suitable for administration using tube. | 06-30-2011 |
| 20110144339 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND - The invention provides an industrial method for producing a spiroaminopyrrolidone derivative, which is an intermediate for producing a quinolone antibacterial agent. Specifically, the invention provides a method for producing a compound of formula (2): | 06-16-2011 |
| 20110124692 | CRYSTALLINE FORMS OF THIAZOLIDINEDIONE COMPOUND AND ITS MANUFACTURING METHOD - Thiazolidinedione compound crystalline forms useful as a bulk material for the manufacture of a peroxisome proliferator-activated receptor (PPAR) γ activator or an anticancer pharmaceutical composition are provided, which are hydrate crystalline forms of 5-(4-{[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1-H-benzimi dazol-2-yl]methoxy}benzyl)-1,3-thiazolidine-2,4-dione represented by Formula (I) below and of its dihydrochloride. | 05-26-2011 |
| 20110112103 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND - The present invention provides compounds which promote erythropoietin production. Compounds represented by the following general formula (1) or pharmacologically acceptable salts thereof are provided: | 05-12-2011 |
| 20110092713 | METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND - The present invention provides a method for producing a 1-biphenylmethylimidazole compound having superior angiotensin II receptor antagonistic activity, or an intermediate thereof. | 04-21-2011 |
| 20110092555 | Thiazolidinedione compound - A compound which is 5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]benzyl}thiazolidine-2,4-dione hydrochloride, in crystal form wherein a powder x-ray diffraction pattern obtained by irradiation with a Cu Kα line shows main peaks at interplanar spacings d=14.29, 7.12, 5.34, 4.97, 4.74, 3.95, 3.85, 3.75, 3.55, 3.51, 3.15, 2.84, 2.76, 2.52 and 2.37. | 04-21-2011 |
| 20110082138 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES - A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof. | 04-07-2011 |
| 20110077266 | Diamine Derivatives - The present invention relates to diamine compounds which inhibit activated blood coagulation factor X and exhibit an anticoagulant effect and there uses for treating various diseases based on thromboembolism. | 03-31-2011 |
| 20110071170 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES - A pyrazolopyrimidine compound represented by formula (1) that inhibits the function of HSP90 as a chaperone protein and that has antitumor activity, a medicament comprising a compound represented by formula (1), a pharmaceutical composition comprising a compound represented by formula (1), and a method for treating cancer using a compound represented by formula (1). | 03-24-2011 |
| 20110053974 | CARBOXYLIC ACID COMPOUND - To find a therapeutic agent and/or a preventive agent for diabetes mellitus or the like having excellent activity and safety. A compound represented by the following general formula (I), or a pharmacologically acceptable salt thereof. In the formula, X represents ═C(R5)- or ═N—; Y represents —O— or —NH—; L represents a bond or a substitutable C1-C3 alkylene group; M represents a substitutable C3-C10 cycloalkyl group, a substitutable C6-C10 aryl group, or a substitutable heterocyclic group; R | 03-03-2011 |
| 20110053933 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE - The present invention provides a novel hydroxyquinoxaline carboxamide derivative that is useful for preventing and/or treating blood coagulation disorders. A compound represented by formula (i), or a pharmacologically acceptable salt thereof: | 03-03-2011 |
| 20110039783 | PEPTIDE HAVING HYPOTENSIVE ACTIVITY - The present invention provides a novel peptide having a physiological activity. Because of having a hypotensive activity, this novel peptide is useful in treating a disease caused by hypertension. Also, an antibody to the novel peptide is provided. | 02-17-2011 |
| 20110014651 | METHOD FOR HIGH-LEVEL SECRETORY PRODUCTION OF PROTEIN - This invention provides a means for high-level secretory production of a protein, and, in particular, a protein having a complicated structure such as an antibody, in a host cell such as a yeast cell. This invention provides a method for high-level secretory production of a foreign protein with the use of a transformed host cell having one or more types of chaperone protein genes and via suppression of O sugar chain inherent to a host cell such as a yeast cell. | 01-20-2011 |
| 20110009471 | Oligonucleotide analogues and methods utilizing the same - A method for the prevention or treatment in a mammal of a disease preventable or treatable by the pharmacologically useful antisense or antigene activity of an oligonucleotide analogue or a pharmacologically acceptable salt thereof in the body of said mammal, which method comprises administering to said mammal in need of such prevention or treatment a pharmaceutically effective amount of an oligonucleotide analogue comprising two or more nucleoside units, wherein at least one of said nucleoside units is a structure of the formula (2): | 01-13-2011 |
| 20100310597 | ANTI-OFLOXACIN MONOCLONAL ANTIBODY AND IMMUNOASSAY OF OFLOXACIN USING THE SAME - A method that accurately and conveniently detects a compound shown by the formula (I) in a human sample is disclosed. An antibody that reacts with the compound shown by the formula (I), but does not cross-react with the N-oxide metabolite and the desmethyl levofloxacin metabolite of the compound shown by the formula (I) is prepared using an antigen produced by binding bovine serum albumin to the compound shown by the formula (I) through the 6-position carboxyl group. | 12-09-2010 |
| 20100297767 | NOVEL CELL CULTURE AND METHODS OF PRODUCING AND COLLECTING CELL MASSES USING THE SAME - The inventors of the present invention have developed a novel cell culture method with a view to providing a process by which cell masses uniform in size and properties can be produced in large quantities and with convenience, as well as a method of recovering them. | 11-25-2010 |
| 20100292259 | PYRIMIDYL INDOLINE COMPOUND - It is intended to provide a pyrimidyl indoline compound which structurally differs from compounds used as active ingredients in conventional oral hypoglycemic agents and has excellent hypoglycemic effect. The present invention provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof: | 11-18-2010 |
| 20100248227 | DRUG-PHOSPHORYLATING ENZYME - The objects of the present invention are: elucidation of an enzyme that phosphorylates in vivo a compound such as (2R)-2-amino-2-methyl-4-[5-(5-phenylpentanoyl)thiophen-2-yl]butan-1-ol and provision of a method of phosphorylating the aforementioned compound; provision of a method of screening for a substance phosphorylated by the aforementioned enzyme; provision of a method of determining the ability of a subject to phosphorylate a test compound. | 09-30-2010 |
| 20100237530 | COMPRESSED PREPARATION | 09-23-2010 |
| 20100234410 | HYDRATE FOR MEDICAL PURPOSES - The present invention relates to [7-[(7S)-7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid hemihydrate. This hemihydrate is stable and easy to prepare, and has excellent properties for a pharmaceutical bulk powder. | 09-16-2010 |
| 20100221335 | SUSTAINED-RELEASE PREPARATION AND METHOD FOR PRODUCING THE SAME - The present invention provides a preparation which is a sustained-release preparation capable of providing a dissolution profile that permits once-daily administration even in the case of a highly water-soluble drug, and which can exhibit stable drug dissolution behavior and can be reduced in its size; and a method for producing the same. A preparation containing a highly water-soluble drug, a gel-forming polymer, and a low-melting lipophilic substance is usable as a sustained-release preparation that permits once-daily administration, and enables reduction in its size and simple production thereof, and thus, the objects have been achieved. | 09-02-2010 |
| 20100209490 | IMMUNOLIPOSOME INDUCING APOPTOSIS INTO CELL EXPRESSING DEATH DOMAIN-CONTAINING RECEPTOR - The present invention relates to an immunoliposome preparation having a therapeutic effect on cancer, autoimmune disease, or inflammatory disease. Specifically, the present invention relates to an immunoliposome comprising, as a constituent, an antibody capable of inducing the apoptosis of cells expressing a death domain-containing receptor. | 08-19-2010 |
| 20100183618 | ANTI-EPHA2 ANTIBODY - Problem to Be Solved | 07-22-2010 |
| 20100168136 | ALKYLSULFONE DERIVATIVES - A compound having activity to inhibit production and/or secretion of β-amyloid protein, and is useful for prevention and/or treatment of various diseases associated with abnormal production and/or secretion of β-amyloid protein, the compound represented by the general formula (I): | 07-01-2010 |
| 20100152467 | METHOD FOR PRODUCING CERCOSPORAMIDE - The present invention provides a process for producing cercosporamide comprising culturing a fungus belonging to the genus | 06-17-2010 |
| 20100136011 | ANTIBODIES THAT BIND TO OBM - Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease. | 06-03-2010 |
| 20100130768 | METHOD FOR HYDRODEHALOGENATION OF ORGANIC HALOGEN COMPOUND - The present invention relates to a hydrodehalogenation method in which a halogen atom on a carbon atom of an organic compound is removed by substituting the halogen atom with a hydrogen atom, and to a method for producing a dehalogenated compound. The hydrodehalogenation method is characterized by including treating an organic compound having a halogen atom on a carbon atom thereof in a solvent with a compound represented by formula (2-1): | 05-27-2010 |
| 20100130567 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE - A method of treating or preventing Alzheimer's disease or mild cognitive impairment which is an early state of cognitive impairment including Alzheimers' disease by administering a pharmacologically effective amount of an angiotensin II receptor blocker. A method of improving cerebral circulation or cerebral blood flow disorder by administering a pharmacologically effective amount of an angiotensin II receptor blocker. A method of treating or preventing amyloid β-induced brain disfunction by administering a pharmacologically effective amount of an angiotensin II receptor blocker. | 05-27-2010 |
| 20100130492 | MORPHOLINOPURINE DERIVATIVES - There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity: | 05-27-2010 |
| 20100125131 | Gene Encoding A Guanine Nucleotide Exchange Factor And The Gene Product Thereof - A gene encoding a novel protein that works as a guanine nucleotide exchange factor (GEF) for a Rho family protein being one group of small GTP-binding proteins, namely, a polynucleotide shown by the nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5, or the complementary strand, the equivalents of the polynucleotide, a protein encoded by the polynucleotide, a vector containing the polynucleotide, a transformant containing the vector, an antibody against the protein encoded by the polynucleotide, a method of identifying a compound that inhibits the function of the protein encoded by the polynucleotide and/or the expression of the polynucleotide, a method of determining a disease, a pharmaceutical composition, and a reagent kit are provided. | 05-20-2010 |
| 20100113410 | PYRAZOLOPYRIMIDINE DERIVATIVE - Problem to be Solved To provide a novel compound inhibiting the effect of HSP90, in particular a novel compound inhibiting the function of HSP90 as a chaperone protein and having antitumor activity.
| 05-06-2010 |
| 20100098753 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR CARDIAC INFARCTION - The present invention relates to a novel preventive and/or therapeutic drug for myocardial infarction. | 04-22-2010 |
| 20100093826 | ATROPISOMER OF PYRROLE DERIVATIVE - [Object] A prophylactic or therapeutic agent for a cardiovascular disease is provided. | 04-15-2010 |
| 20100081685 | PHARMACEUTICAL COMPOSITION - To provide pharmaceutical preparation exhibiting satisfactory dissolution property in a wide pH range. | 04-01-2010 |
| 20100063279 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE - The present invention relates to a method for producing a quinolone compound having high antibacterial activity and high safety, at high yield and in a simple manner. | 03-11-2010 |
| 20100062070 | Pulverzed crystals of olmesartan medoxomil - An olmesartan medoxomil having a particle diameter at 90% cumulative volume of 75 μm or less, which provides an improved dissolution property. The olmesartan medoxomil is advantageously used to treat or prevent hypertension or a disease caused by hypertension. | 03-11-2010 |
| 20100048564 | FUSED BICYCLIC HETEROARYL DERIVATIVE - The present invention relates to a novel fused bicyclic heteroaryl derivative or a pharmacologically acceptable salt thereof, which has an excellent hypoglycemic effect or treats and/or prevents the onset of a disorder of carbohydrate or lipid metabolism or a disease mediated by peroxisome proliferator-activated receptor (PPAR) γ. | 02-25-2010 |
| 20100016714 | SYRINGE OUTER TUBE FOR CHEMICAL SOLUTION FILLED AND SEALED SYRINGE FORMULATION AND PROCESS FOR PRODUCING THE SAME - A syringe barrel for pre-filled syringe formulation capable of suppressing the adhesion of air bubbles, and a pre-filled syringe formulation having the adhesion of air bubbles suppressed, are provided, and a process allowing efficient production of the syringe barrel is provided. | 01-21-2010 |
| 20100010214 | LYOPHILIZED PREPARATION OF 1-METHYLCARBAPENEM - A lyophilized preparation comprising (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-1-methyl-2-[(2S,4S)-2-[(3S)-3-(2-guanidinoacetylamino)pyrrolidin-1-ylcarbonyl]-1-methylpyrrolidin-4-ylthio]-1-carbapen-2-em-3-carboxylic acid or a pharmacologically acceptable salt thereof as a carbapenem compound, which has a 1-alkylpyrrolidine structure and possesses a superior antimicrobial activity, and sodium chloride. | 01-14-2010 |
| 20100004221 | THIAZEPINE DERIVATIVE - Thiazepine derivative or a pharmacologically acceptable salt thereof having an effect of inhibiting 11β-hydroxysteroid dehydrogenase type 1 and having a formula (1): | 01-07-2010 |
| 20090324581 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE - To provide a novel compound which has S1P receptor agonistic activity, exhibits excellent immunosuppressing effect, gives less adverse side effects, and can be orally administered. | 12-31-2009 |
| 20090306151 | Pharmaceutical preparation containing an angiotensin II receptor antagonist and a calcium channel blocker - A pharmaceutical preparation comprising an angiotensin II receptor antagonist, a calcium channel blocker and at least one substance selected from a hydrophilic polymer, an acidic substance and a fluidizing agent. The pharmaceutical preparation demonstrates improved dissolution properties. | 12-10-2009 |
| 20090292024 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - It is an object of the present invention to provide a substituted propanamide derivative or a pharmacologically acceptable salt thereof that is useful as a prophylactic or therapeutic agent for a bone metabolic disease. The present invention relates to a pharmaceutical composition comprising a compound having General Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: | 11-26-2009 |
| 20090291138 | FILM-COATED PREPARATION HAVING IMPROVED STABILITY - A film-coated preparation having excellent storage stability, which contains a compound represented by the formula (I) below or a pharmacologically acceptable salt thereof, having a film layer containing one or more film coating base agents selected from polyvinyl alcohol, sodium carboxymethyl cellulose and pullulan. The formula (I) is as follows: | 11-26-2009 |
| 20090286807 | CYCLIC AMINE COMPOUND - The present invention provides an excellent antihypertensive medicament. The medicament of the present invention comprises a compound having the general formula (I) and the like: | 11-19-2009 |
| 20090270637 | PROCESS FOR PREPARATION OF TETRASUBSTITUTED 5-AZASPIRO[2.4]- HEPTANE DERIVATIVES AND OPTICALLY ACTIVE INTERMEDIATES THEREOF - The present invention provides a method for effectively producing an optically active form of tetrasubstituted-5-azaspiro[2.4]heptane derivative, which serves as a useful production intermediate for quinolonecarboxylic acid antibacterial agents, and intermediates for the derivative. The present invention is directed to a method for producing a compound (VII) according to the following scheme. | 10-29-2009 |
| 20090253683 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF - A 7-membered heterocyclic compound having the formula (I), or its salt, or a solvate thereof with a chymase inhibitory action and useful for the prevention or treatment of various diseases, in which chymase is involved: | 10-08-2009 |
| 20090239857 | TRIAMINE DERIVATIVE - An object of the present invention is to provide a novel compound which has a potent inhibitory effect on FXa and exhibits an excellent antithrombotic effect when orally administered. The present invention provides a compound represented by the following general formula (1): | 09-24-2009 |
| 20090233366 | COMPOSITION FOR INTRODUCTION OF NUCLEIC ACID - Composition with weak cytotoxicity for introducing a nucleic acid, such as a short oligonucleotide or a gene, into a cell for expression of the gene in the cell. The composition includes a lipid and a compound represented by a formula (I): | 09-17-2009 |
| 20090215901 | Methods for treatment of nocturia - A method for the treatment of nocturia which consists of administering to a mammal in need of such treatment a therapeutically effective amount of a nonsteroidal anti-inflammatory drug consisting of loxoprofen or a pharmacologically acceptable salt thereof, wherein the mammal is a human who has a neurogenic bladder. | 08-27-2009 |
| 20090203073 | Gene Encoding G-Protein Coupled Receptor and Gene Product Thereof - The present invention, the objects of which are to find out a gene encoding a protein having functions equivalent to those of G-protein-coupled receptor (GPCR) and the protein, and to provide a method for identifying a compound that regulates functions and/or expression of the protein, and to provide a useful mean for preventing and/or treating diseases related to the gene and the protein, provides a DNA comprising base sequence described in SEQ ID NO: 1 or complementary strand thereof, complementary strand of the DNA, a protein encoded by the DNA, a vector containing the DNA, a transformant containing the vector, an antibody against the protein, a method for identifying a compound that regulates functions and/or expression of the protein using aforementioned members, an agent for improving and a method for improving depression state, a pharmaceutical composition, and a reagent kit. | 08-13-2009 |
| 20090191587 | METHOD FOR HIGH-LEVEL SECRETORY PRODUCTION OF PROTEIN - This invention provides a means for enabling high-level secretory production of proteins, in particular proteins having complicated structures such as antibodies, in host cells such as yeast cells. The invention also provides transformed yeast cells having the activated HAC1 gene and the RRBP1 gene and a method for enabling high-level secretory production of foreign proteins using such transformed host cells by inhibiting O-sugar chain formation indigenous to host cells such as yeast cells. | 07-30-2009 |
| 20090186868 | Taxane Compound Having Azetidine Ring Structure - A compound represented by the general formula (1) [X | 07-23-2009 |
| 20090175942 | Solid Dosage Form of Olmesartan Medoxomil And Amlodipine - The invention relates to a stable solid dosage form comprising olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof. In particular, it relates to solid dosage forms free from reducing sugars. The stable solid dosage form may optionally further comprise hydrochlorothiazide or a pharmacologically acceptable salt thereof. | 07-09-2009 |
| 20090170827 | Acid Addition Salt of Dihydropyridine Derivative - There is provided an excellent medicine for treating or preventing hypertension or the like. A specific acid addition salt of 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester is useful as a medicine for treating or preventing hypertension or the like. | 07-02-2009 |
| 20090170826 | Acid Addition Salt of Optically Active Dihydropyridine Derivative - There is provided an excellent medicine for treating or preventing hypertension or the like. A specific acid addition salt of (R)-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenyl-methylazetidin-3-yl) ester 5-isopropyl ester is useful as a medicine for treating or preventing hypertension or the like. | 07-02-2009 |
| 20090162283 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION - To provide a diagnostic drug which binds specifically to an amyloid aggregate and/or an amyloid deposit, to thereby realize imaging and quantification of a disease caused by amyloid aggregation and/or deposition. | 06-25-2009 |
| 20090149439 | PYRIDYLMETHYSULFONE DERIVATIVE - The present invention relates to a novel compound having an effect of inhibiting production/secretion of β-amyloid protein. The present invention provides a compound represented by the general formula (1): | 06-11-2009 |
| 20090149404 | Oligonucleotide analogues and methods utilizing the same - A method for the prevention or treatment in a mammal of a disease preventable or treatable by the pharmacologically useful antisense or antigene activity of an oligonucleotide analogue or a pharmacologically acceptable salt thereof in the body of said mammal, which method comprises administering to said mammal in need of such prevention or treatment a pharmaceutically effective amount of an oligonucleotide analogue comprising two or more nucleoside units, wherein at least one of said nucleoside units is a structure of the formula (2): | 06-11-2009 |
| 20090143353 | ANTIFUNGAL BICYCLIC HETERO RING COMPOUNDS - A 1,6-β-glucan synthetase inhibitor is provided, having potent growth inhibition and having excellent safety. | 06-04-2009 |
| 20090124626 | Pharmaceutical agent comprising insulin resistance improving agent - To provide a method for treating diabetes which has an excellent hypoglycemic action and causes minimal adverse drug reactions, there is provided a medicine comprising a DPP-IV inhibitor and an insulin sensitizer in combination. | 05-14-2009 |
| 20090118199 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - A pharmaceutical composition comprising a compound having Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: | 05-07-2009 |
| 20090105491 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME - The invention is directed to a process for producing intermediates of a compound which exhibits an activated blood coagulation factor Xa inhibitory action and which is a useful preventive and a therapeutic agent for thrombotic diseases. The intermediate production process is represented by the following reaction scheme. | 04-23-2009 |
| 20090088462 | Pharmaceutical Composition for Enhancing Adiponectin Production - Method for treatment of a human patient having hypoadiponectinemia. 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione or a pharmacologically salt thereof is administered in an amount effective to raise the level of adiponectine in said patient. | 04-02-2009 |
| 20090062404 | PHARMACEUTICAL COMPOSITION - The present invention provides an intraoral rapid-disintegrating pharmaceutical composition which exhibits excellent intraoral disintegrating property and high hardness, and which can be applied, in particular, to a pharmaceutically active ingredient which is unstable in water. The pharmaceutical composition, which contains lactose and powdered cellulose, exhibits high hardness without prolongation of its intraoral disintegration time. When a disintegrating agent is further incorporated into the pharmaceutical composition, the hardness of the composition is increased without prolongation of its intraoral disintegration time. When magnesium aluminometasilicate, and one or more species selected from among silicic acid and silicic acid salts other than magnesium aluminometasilicate are further incorporated into the pharmaceutical composition, the composition exhibits higher hardness without prolongation of its intraoral disintegration time. The pharmaceutical composition of the present invention can be produced by means of a generally employed industrial production process without using a special preparation technique. | 03-05-2009 |
| 20090054648 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND - The invention provides an industrial method for producing a spiroaminopyrrolidone derivative, which is an intermediate for producing a quinolone antibacterial agent. | 02-26-2009 |
| 20090028868 | Anti-cancer pharmaceutical compositions and methods for treating patients with cancer - Method of treating persons having carcinoma, sarcoma or hematopoietic cancer by administering (i) a compound of the formula (I) | 01-29-2009 |
| 20090012119 | FLUOROALKYLPYRROLIDINE DERIVATIVE - This invention relates to a compound represented by the following formula (1): | 01-08-2009 |
| 20080300403 | Method for Production of Quinolone-Containing Lyophilized Preparation - The present invention is directed to a lyophilized preparation which contains a synthetic quinolone antibacterial compound and, as a solo additive, a pH-adjusting agent, and which exhibits an excellent reconstituting property. The invention provides a method for producing a lyophilized preparation containing a synthetic quinolone antibacterial compound as an active ingredient, characterized by including, sequentially, cooling an aqueous solution containing a synthetic quinolone antibacterial compound and a pH-adjusting agent to yield a frozen product, elevating the temperature of the frozen product, and re-cooling the resultant to prepare the lyophilized preparation. | 12-04-2008 |
| 20080214626 | Methods for prevention and treatment of diseases causes by hypertension - A method for the prevention and/or treatment of a disease caused by hypertension comprising administering to a mammal, such as a human, in need thereof pharmaceutically effective amounts of (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2′-(1H-tetrazol-5-yl(biphenyl-4-yl]methyl]imidazol-5-carboxylate and a calcium channel blocker which is amlodipine or amlodipine besylate. | 09-04-2008 |
